Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicol Renesova

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|September 28, 2021
BH3 Mimetics in Hematologic MalignanciesPavel Klener, Dana Sovilj, Nicol Renesova, et al.
Cancers|February 15, 2022
Targeted Drug Delivery and Theranostic Strategies in Malignant LymphomasTomas Etrych, Alena Braunova, David Zogala, et al.
Scientific Reports|June 8, 2026
A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomasEva Pokorna, Dmitry Manakov, Kristyna Nozickova, et al.
Molecular Cancer Therapeutics|November 3, 2021
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell LymphomasMagdalena Klanova, Dmitry Kazantsev, Eva Pokorna, et al.
Cell Death Discovery|February 18, 2025
Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitorsLenka Daumova, Dmitry Manakov, Jiri Petrak, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|September 28, 2021
BH3 Mimetics in Hematologic MalignanciesPavel Klener, Dana Sovilj, Nicol Renesova, et al.
Cancers|February 15, 2022
Targeted Drug Delivery and Theranostic Strategies in Malignant LymphomasTomas Etrych, Alena Braunova, David Zogala, et al.
Scientific Reports|June 8, 2026
A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomasEva Pokorna, Dmitry Manakov, Kristyna Nozickova, et al.
Molecular Cancer Therapeutics|November 3, 2021
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell LymphomasMagdalena Klanova, Dmitry Kazantsev, Eva Pokorna, et al.
Cell Death Discovery|February 18, 2025
Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitorsLenka Daumova, Dmitry Manakov, Jiri Petrak, et al.
Pageof 1